映恩生物-B（09606）今日盘中大涨15%，股价一度触及232.8港元，创上市以来新高。截至11时52分，该股涨幅收窄至15%，报230.2港元，成交额超1.75亿港元。
映恩生物是全球抗体偶联药物（ADC）领域的领先企业，专注于为癌症和自身免疫性疾病患者研发创新ADC药物。公司拥有两款自主研发的核心产品，并有五项处于临床阶段的资产已获得美国FDA和中国国家药监局的研究用新药批准。其中，DB-1303和DB-1311两款产品在临床试验中展现出良好的治疗潜力。
国泰海通证券近期发布研报，给予映恩生物-B"增持"评级，目标价300.70港元。分析师指出，公司的DB-1303产品相比同类药物Enhertu表现更优，而DB-1311在小细胞肺癌（SCLC）和去势抵抗性前列腺癌（CRPC）治疗方面有望取得突破。此外，映恩生物产品管线丰富，ADC布局持续扩容，预计2025-2027年收入将稳步增长。券商的积极评级进一步提振了投资者信心，推动股价创下新高。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.